Harness the power of AI for CAD diagnosis
AI for heart disease diagnosis
Salix is a non-invasive diagnostic support solution to detect coronary artery disease. The cloud-based software draws on thousands of computed tomography coronary angiography (CTCA) scans to automatically detect vulnerable plaque, stenosis and other biomarkers in a patient’s cardiovascular system, all within minutes.
This is a critical advance to evaluate cardiovascular disease and guide diagnostic options for clinicians.
Seeing heart disease in a new way
Heart disease is the world’s number one cause of death and leads to about one in three deaths annually, according to the World Health Organization. Coronary artery disease (or ischemic heart disease) is the most common type of heart disease affecting around 126 million people worldwide and is the leading cause of heart attack. Sadly, 9 million individuals will die from coronary artery disease each year. Yet there have been few diagnostic advances since the 1970s - until now.
Salix unlocks the capability to triage patients into risk categories, identifying which patients require further clinical assessments.
Identifying the cause of heart attack
Historically, vulnerable plaque has been challenging to see and report. Salix is changing the paradigm for diagnosis. It offers a precision-medicine solution for heart disease monitoring. It prioritises the detection of vulnerable plaque in addition to calcium build-up, stenosis and plaque burden. This creates a comprehensive heart-health image for each patient.
With early detection of vulnerable plaque, clinicians are empowered to offer targeted therapy sooner, which could alter a patient's heart disease prognosis.
Changing how the world sees heart disease
Salix product features
Assessment in ~10 mins
Personalised precision medicine in minutes
The Salix algorithm has been trained on thousands of existing scans. From a single patient scan, each artery is assessed independently and visualised in a precise 3D model.
The report is automatically completed in real-time, at the point of care. This reduces the reporting time from days and hours to ~10 minutes.
Patient 3D heart model
Comprehensive cardiovascular risk profiles
You are provided with a holistic report of your patients' coronary artery disease. This includes an unprecedented combination of key findings comprising vulnerable plaque, percentage of stenosis, and total plaque burden.
High-risk patient identification at a glance
The traffic-light dashboard provides an immediate visual guide to high-risk results so clinicians can triage patients early and determine who requires more aggressive treatment to reduce the likelihood of a major adverse cardiac event.
Automated and Augmented
A fully written report with key coronary findings is presented on a single screen.
Detailed assessments of the major arteries (LM, LCX, LAD and RCA) and sub-branches are provided, offering healthcare professionals instant access to critical information.
Clinicians receive full control to accept or modify the assessment results. For ease of use, pre-set criteria are available in drop down form to automatically edit a report if needed.
Patient scans can be sent directly to a second clinician for additional assessment, providing further certainty on complex cases.
Salix integrates with industry leading picture archiving and communication systems.
First principle analysis
Automated, in-depth data side by side
Advanced functionality delivers automated centre-line tracking, segmenting, annotating, detecting, and calculating disease with complementary raw data available for analysis too.
"Salix provides a complete view of a patient’s cardiovascular risk as well as real time reporting. We were able to identify high risk patients accurately within minutes. This allows us to focus on the right patients at the right time with the right treatment." - Australian Cardiologist
Built on thousands of scans from partnering clinics.
Highly accurate, validated data.
Cut reporting times from hours to ~10 minutes with a single scan.
Fast, efficient and accurate.
Frequently asked questions
Artrya has nurtured successful collaboration with globally recognised cardiology research institutions, including: University of Western Australia (UWA), Harry Perkins Institute of Medical Research, and Ottawa Heart Institute. Artrya has also partnered with Envision Medical Imaging to commence Australian commercialisation.
Not yet. Artrya is seeking international regulatory approvals for other countries globally. Today, we're authorised to commercialise across Australia. Please register your interest with us via the page or sign up to our newsletter to follow our progress.
Salix is cloud-based, secured with a direct VPN from PACS to cloud to maintain the highest level of encryption and security. Salix is accessed by a unique login using a secured web browser, which enables full functionality and analysis with no on-site hardware requirements.
Artrya is actively seeking partners globally across a number of areas from clinical investigations to market trials. Please register your interest to collaborate with us via the . For practices located in Australia, we can work with you to implement Salix in to your daily workflows.